1/56
Looks like no tags are added yet.
Parts of IBD disease burden
Inflammatory activity
Disability
Symptoms + Quality of life
Psychological health
Hospitalizations and surgery
Assessing disease severity
Inflammatory burden - mucosal lesions, biomarkers
Diseases impact on patients - quality of life, symptoms
Complicated Disease course - recurrent flares, intestinal damage, disease phenotype
Impact of patient on disease - coping strategies, healthcare utilization, shared decision making, treatment adherence
Disease phenotype
Displayed traits like age, location, and behavior
Goals of IBD Therapy
Symptomatology/Response
Remission
Mucosal healing
Quality of life
Alter disease course
Short term goals of IBD treatment
Symptom improvement (HBI, CDAI, SCCAI)
Biochemical response/remission
Quality of life and psychological health
When to reassess short term goals
6-12 weeks
Intermediate goals of Therapy for IBD
Symptom remission
Mucosal healing
Quality of life and psychological health
When to reassess intermediate goals
every 6-12 months
Long term goals of therapy for IBD
Reduce disability
Reduce dysplasia
Alter natural history of disease
When to reassess long term goals
1-5 years
Treat to target IBD
Set a predefined therapeutic goal and monitor it
Short Term Target
Clinical Response
>50% decrease in PRO2
Intermediate Target
Clinical remission and biomarker normalization
Additional long-term target
Restore QoL, decrease disability
Long term target
Endoscopic healing
Malabsorption/nutritional support NonPharm
Enteral nutrition is effective, some patients may need tube feeding
Parenteral nutrition is reserved for complicated disease or patients who tried parenteral and are not gaining weight
Screen for micronutrient deficiencies
Probiotics Nonpharm
Help support normal GI microbiome but can be expensive and hard to time dosing
Exacerbating factors of IBS
Smoking, Infections, NSAID use, stress
Surgery for IBD
Potentially curative for UC
High recurrence rates for CD
Usually need to get an ostomy while healing
T2T Goals
Resolution of acute disease symptoms
Induction and maintenance of remission
What determines IBD treatment (dose, route, frequency)
Severity
Extent
Location
Disease Complications
Pharmacologic Therapy for mild to moderate disease
Amino salicylates
Corticosteroids
Antimicrobials
Pharmacologic therapy for moderate-severe or fulminant diseases
Immunomodulators
mAbs and TNF-a antibodies
Kinds of aminosalicylates
Sulfasalazine
Mesalamine
Balsalazide
Olsalazine
All contraindicated in a salicylate allergy
Sulfasalazine (Azulfidine)
Combination of sulfonamide antibiotic (sulfapyridine) and mesalamine. Less expensive. Contraindicated with sulfa allergy.
Sulfasalazine AEs
Are dose dependent (>4 grams)
N/V, anorexia, alopecia, GI distress, HA, oligospermia, pancreatitis, blood dyscrasias, interstitial nephritis
Blood dyscrasiasis
agranulocytosis, aplastic anemia
Not producing enough neutrophils + bone marrow is not producing any blood cells
Managing Sulfasalazine AEs
For acute intolerance - discontinue or restart at lower dose and titrate uo
Give with food
Co prescribe folic acid 1mg/day to prevent anemia
Use mesalamine alone
Mesalamine PK
Design drugs to deliver mesalamine to affected areas w/o premature absorption
Completely absorbed in small intestine
Poorly absorbed in colon, but exerts local effect
Mesalamine
Better tolerated than sulfasalazine
AEs of mesalamine
Nausea, dyspepsia, abdominal cramping, diarrhea, HA, pancreatitis, arthralgia, cutaneous reactions
Types of UC + dosage form
Ulcerative Proctitis - suppository
Left-sided colitis -suppository + enema
Pancolitis - PO
Pentasa
Works in duodenum-rectum
Diffusion dependent
Delzicol, Apriso
pH-dependent, enteric coating, enteric coating + polymer matrix
Proximal colon - rectum
Asacol
pH-dependent, enteric coating
Terminal ileum - rectum
Lialda
pH + MMX + enteric coating
Proximal colon - rectum
Balsalazide
Mesalamine prodrug
Uses an inert carrier molecule to transport mesalamine to the colon
Undergoes enzymatic cleavage to release mesalamine
Olsalazine
Bacteria cleave olsalazine, releasing mesalamine.
Dose dependent diarrhea, 15-35% incidence
Corticosteroids
Suppress acute inflammation
Modulate the immune system and inhibit cytokine and inflammatory mediators
May be given orally, rectally, parenterally in moderate-severe or fulminant disease
Budesonide (Uceris, Entocort EC)
Oral, controlled release
Releases in the terminal ileum or colon
Low systemic bioavailability due to 1st pass metabolism, less AEs
May minimize adrenal suppression compared to other steroid options
Also available in rectal foam for distal disease
Prednisone
Oral
Requires tapering if used long-term
Increased risk of osteoporosis - consider vit D and calcium supplements
(1000-1200 calcium, 600-800 units D)
DEXA scan
Antimicrobial agents for IBD
Limited role as adjunctive therapy. Use metronidazole. Usually used for perianal fistulas
Perianal Fistulas
Communicates with exterior or another body cavity
Often formed from an abscess that can’t heal
Risks of long term metronidazole use
C. diff
Antibiotic resistance
Neurotoxicity
Induction mild-moderate proctitis regimen
5-ASA supp 1g/day
or
5-ASA enema >/= 1g/day
Induction left sided colitis regimen
5-ASA enema >/= 1g/day + PO 5-ASA >/= 2g/day
Induction Extensive/Pancolitis regimen
5-ASA PO >/= 2g/day
Budesonide MMX 9mg/day
UC not responding to PO 5-ASA
Use oral budesonide MMX 9mg/day to induce remission
Goals of CD treatment
Induce remission
Mucosal healing
Improve quality of life/mental health
Why is CD more difficult to treat than UC
Complexity of presentation
Aggressive nature of the disease
Greater reliance on drugs, surgery more difficult
Poor prognostic factors of CD
Young age at time of diagnosis
Ileal/ileocolonic involvement
Initial extensive bowel involvement
Perianal/severe rectal disease
Deep ulcers
Penetrating or stricturing phenotype at diagnosis
Extraintestinal manifestations at diagnosis
Induction of mild colonic or ileocolonic CD
Sulfasalazine 3-6g/day divided into 3-6 doses
Induction of mild-moderate ileocecal CD
Budesonide PO 9mg/day for controlled ileal release
Is oral mesalamine recommended for CD
No
What treatments are discouraged for CD maintenance
PO mesalamine
PO budesonide
Is there any agent endorsed for maintenance of CD
No, generally need immunologic therapy